S
Shelly Zaffryar-Eilot
Researcher at Technion – Israel Institute of Technology
Publications - 15
Citations - 1119
Shelly Zaffryar-Eilot is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Lysyl oxidase & LOXL2. The author has an hindex of 7, co-authored 12 publications receiving 933 citations. Previous affiliations of Shelly Zaffryar-Eilot include Rappaport Faculty of Medicine.
Papers
More filters
Journal ArticleDOI
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
Vivian Barry-Hamilton,Rhyannon Spangler,Derek Marshall,Scott Alan Mccauley,Hector Rodriguez,Miho Oyasu,Amanda Mikels,Maria Vaysberg,Haben Ghermazien,Carol Wai,Carlos Aurelio Garcia,Arleene C. Velayo,Brett Jorgensen,Donna Hiroko Tokuoka Biermann,Daniel Tsai,Jennifer Green,Shelly Zaffryar-Eilot,Alison Kay Holzer,Scott Ogg,Dung Thai,Gera Neufeld,Peter Van Vlasselaer,Victoria Smith +22 more
TL;DR: Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models and outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile.
Journal ArticleDOI
Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.
Chen Rachman-Tzemah,Shelly Zaffryar-Eilot,Moran Grossman,Dario Ribero,Michael Timaner,Joni M. Mäki,Johanna Myllyharju,Francesco Bertolini,Dov Hershkovitz,Irit Sagi,Peleg Hasson,Yuval Shaked +11 more
TL;DR: It is shown that in response to surgery, the lungs become more vulnerable to metastasis due to extracellular matrix remodeling, and downregulation ofLOX activity or levels reduces lung metastasis after surgery and increases survival, highlighting the potential of LOX inhibition in reducing the risk of metastasis following surgery.
Journal ArticleDOI
Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours
Shelly Zaffryar-Eilot,Derek Marshall,Tali Voloshin,Avinoam Bar-Zion,Rhyannon Spangler,Ofra Kessler,Haben Ghermazien,Vera Brekhman,Edith Suss-Toby,Dan Adam,Yuval Shaked,Victoria Smith,Gera Neufeld +12 more
TL;DR: Administration of the LOXL2-neutralizing antibody AB0023 inhibited bFGF-induced angiogenesis in Matrigel plug assays and suppressed recruitment ofAngiogenesis promoting bone marrow cells, suggesting that inhibition of LOXL1 may prove beneficial for the treatment of angiogenic tumours.
Journal ArticleDOI
The Enzymatic Activity of Lysyl Oxidas-like-2 (LOXL2) Is Not Required for LOXL2-induced Inhibition of Keratinocyte Differentiation
Jennie Lugassy,Shelly Zaffryar-Eilot,Sharon Soueid,Amit Mordoviz,Victoria Smith,Ofra Kessler,Gera Neufeld +6 more
TL;DR: Surprisingly, a point-mutated form of LOXL2 (LOXL2Y689F) lacking enzymatic activity, as well as a LOXL 2 deletion mutant lacking the entire catalytic domain, also inhibited calcium or vitamin D-induced up-regulation of involucrin expression, suggesting that the enzymatics activity of LO XL2 is not required for this activity.
Journal ArticleDOI
Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2
Vera Brekhman,Jennie Lugassie,Shelly Zaffryar-Eilot,Edmond Sabo,Ofra Kessler,Victoria Smith,Hana Golding,Gera Neufeld +7 more
TL;DR: The experiments suggest that the protumorigenic effects of LOXL2 are partially mediated by RAMP3 and thatRAMP3 inhibitors may function as antitumorigic agents.